Introduction
============

The Juvenile Arthritis Disease Activity Score (JADAS) ^1^ is becoming widely accepted in juvenile idiopathic arthritis (JIA) for defining a treat to target strategy.

Objectives
==========

To evaluate patients (pts) treated with adalimumab (ADA) (±methotrexate \[MTX\]) that achieved minimal disease activity (MDA) and both MDA and normalization of function.

Methods
=======

This *post hoc* analysis assessed pts aged 4-17 with polyarticular JIA enrolled in a phase 3 clinical trial (DE038)^2^, which consisted of a 16 week (wk) open-label (OL) lead-in with ADA±MTX, 32wk double-blind (DB) phase with ADA or placebo (PBO)±MTX, and OL extension (OLE) with ADA±MTX up to 346wks. Outcomes were assessed by 27-joint JADAS (JADAS27), based on C-reactive protein, and Childhood Health Assessment Questionnaire Disability Index (CHAQ-DI). MDA was defined as JADAS27\<3.8 and normal function as CHAQ-DI\<0.5. Pts who entered the DB phase were included; data were stratified by MTX treatment (tx) at entry.

Results
=======

At baseline, 75 pts on MTX had a mean JADAS27 of 21.2 and CHAQ-DI of 0.9, and 58 pts who were MTX naïve or had withdrawn from MTX had a mean JADAS27 of 23.8 and CHAQ-DI of 1.2. After 16wks of OL ADA, the mean JADAS27 was 6.1 and 6.7 and CHAQ-DI was 0.4 and 0.5 for ADA+MTX and ADA-MTX, respectively. Clinical improvements were seen at wk48 and wk88, and the mean JADAS27 at wk88 was 2.6, 3.0, 4.3, and 5.0 for ADA+MTX, ADA-MTX, PBO+MTX, and PBO-MTX, respectively. No pts had MDA or normal function at baseline; however, a good proportion achieved MDA and normal function during OL ADA. Fewer pts achieved MDA and normal function in the PBO tx compared with ADA continuation at both wk48 and wk88. Table [1](#T1){ref-type="table"}.

  n (%)     Minimal Disease Activity                                                            
  --------- ----------------------------------------------- ----------- ----------- ----------- --------
  Week 16   28 (37.3)                                       19 (33.9)   NA          NA          NA
                                                                                                
  Week 48   19 (76.0)                                       14 (56.6)   15 (62.5)   13 (68.4)   0.8919
                                                                                                
  Week 88   26 (83.9)                                       20 (76.9)   14 (50.0)   13 (65.0)   0.0075
                                                                                                
            Minimal Disease Activity with Normal Function                                       
                                                                                                
  Week 16   21 (28.0)                                       15 (26.8)   NA          NA          NA
                                                                                                
  Week 48   17 (68.0)                                       12 (48.0)   15 (62.5)   13 (68.4)   0.5155
                                                                                                
  Week 88   24 (77.4)                                       17 (65.4)   14 (50.0)   11 (55.0)   0.0362

P-value based on Cochran-Mantel-Haenszel statistics to test if there was a difference between ADA continuation vs. PBO.

Conclusion
==========

ADA±MTX resulted in a high percentage of pts achieving/sustaining MDA and normal function. Some improvement was seen with PBO during the DB period, but continued ADA tx shows better overall outcomes. A target of comprehensive disease control with MDA and normal function is achievable and aligned with current goals of JIA tx.
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